Brokerages Set Pharvaris N.V. (NASDAQ:PHVS) PT at $41.70

Pharvaris N.V. (NASDAQ:PHVS) has earned a consensus rating of “Moderate Buy” from the thirteen ratings firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $41.70.

PHVS has been the topic of a number of analyst reports. Royal Bank Of Canada assumed coverage on Pharvaris in a research report on Monday, March 9th. They issued an “outperform” rating and a $52.00 price target on the stock. Guggenheim boosted their price objective on Pharvaris from $32.00 to $39.00 and gave the stock a “buy” rating in a research report on Thursday, December 4th. HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of Pharvaris in a research note on Tuesday, March 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a report on Thursday, January 22nd. Finally, Leerink Partners set a $38.00 price target on shares of Pharvaris in a research note on Wednesday, December 3rd.

Hedge Funds Weigh In On Pharvaris

A number of institutional investors and hedge funds have recently modified their holdings of the company. Geode Capital Management LLC increased its holdings in Pharvaris by 41.1% in the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock valued at $952,000 after buying an additional 15,769 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after buying an additional 783 shares during the last quarter. Legal & General Group Plc lifted its holdings in Pharvaris by 17.2% during the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after buying an additional 1,695 shares during the last quarter. Amundi boosted its position in shares of Pharvaris by 2,741,600.0% during the 2nd quarter. Amundi now owns 27,417 shares of the company’s stock worth $489,000 after acquiring an additional 27,416 shares in the last quarter. Finally, HighVista Strategies LLC boosted its position in shares of Pharvaris by 4.3% during the 2nd quarter. HighVista Strategies LLC now owns 23,739 shares of the company’s stock worth $418,000 after acquiring an additional 971 shares in the last quarter.

Pharvaris Trading Down 0.2%

Shares of NASDAQ PHVS opened at $26.13 on Friday. The business’s fifty day simple moving average is $26.83 and its 200-day simple moving average is $25.07. Pharvaris has a 12-month low of $11.51 and a 12-month high of $29.80.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.